## [Partnering opportunities](/partnering/partnering-opportunities "Partnering opportunities") - [Core therapeutic areas](#tabcore-therapeutic-areas-205371) - [Platforms and AI](#tabplatforms-and-ai-205376) - [Out licensing and divestments](#tabout-licensing-and-divestments-398296) - [Other areas](#tabother-areas-205381) ## [Partnering opportunities - Core Therapeutic Areas](/node/600066 "Partnering opportunities - Core Therapeutic Areas") We are looking for high-value, truly differentiating first or best-in-class treatments in: Cardiovascular, renal & metabolic (CRM) #### Focus on areas of high unmet need, build on strong mid/late-stage pipeline Atherosclerosis - ASCVD prevention and treatment - Novel mechanisms beyond LDL-C, Lp(a), HTN, and inflammation. Heart Failure/Atrial Fibrillation - Heart Failure with reduced or preserved ejection fraction - Safer anti-arrhythmic therapies for Afib - Cardiomyopathies, thrombosis, and hypertension Metabolism/Obesity - Novel mechanisms that complement SoC - Better tolerability and weight loss maintenance Nephrology - Chronic Kidney Disease (Stage 3b/4) - Glomerular diseases e.g. IgA Nephropathy (IgAN), Alport Syndrome ![Avi Spier](/sites/novartis_com/files/styles/crop_freeform/public/2025-09/avi-spier.jpg.webp?itok=9FoUGbbs "Avi Spier") #### Avi Spier [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Immunology **Strong foundation and expect 6 Ph3 readouts, >10 Ph2 readouts in next 5 years Dermatology** - Atopic Dermatitis - Chronic Spontaneous Urticaria (CSU) - Hidradenitis Suppurativa - Lichen Planus - Vitiligo **Rheumatology** - Lupus nephritis (LN) - Sjogren's disease - Spondyloarthropathies Systemic Lupus Erythematosus (SLE) **Inflammatory Bowel Disease** - Crohn's Disease - Ulcerative Colitis **Exploratory Areas** - B cell reset - Food allergy - Rheumatoid Arthritis ![Dominic Ehrismann portrait](/sites/novartis_com/files/styles/crop_freeform/public/2021-10/dominic-ehrismann-portrait.jpg.webp?itok=NIZkq8M0 "Dominic Ehrismann portrait") #### Dominic Ehrismann [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Neuroscience **Focus on multiple sclerosis, neuromuscular and neurodegenerative diseases** **Neurodegeneration** - Parkinson’s Disease (PD) - Alzheimer’s Disease - Huntington’s Disease **Neuromuscular** - Amyotrophic lateral sclerosis (ALS) - Larger neuro-muscular indications **Multiple Sclerosis & Immuno-Neurology** - Multiple Sclerosis (MS) - Other neuroimmunology diseases (e.g., CIDP & MG) ![Chris Adams](/sites/novartis_com/files/styles/crop_freeform/public/2025-07/chris-adams.jpg.webp?itok=lpzEcWuJ "Chris Adams") #### Christopher Adams [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Oncology **Focus areas on solid tumors, RLT and hematology** **Solid Tumors** - Breast cancers - Prostate cancers - Lung cancers - Colorectal and pancreatic cancers **Radioligand Therapy** - Identify RLTs or PET imaging agents in solid tumor indications including novel isotopes, chelators, vectors, and targets **Hematology** - Non-Hodgkin lymphoma (NHL) - Acute myeloid leukemia (AML) / Myelodysplastic syndrome (MDS) - Non-malignant hematology, Myeloproliferative Neoplasms (MPN) ![Markus Werner](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/markus-werne.jpg.webp?itok=QFdRZ5O7 "Markus Werner") #### Markus Werner [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) - [Print](/node/600066/printable/print) - [PDF](/node/600066/printable/pdf) ## [Partnering opportunities - Platforms and AI](/node/600101 "Partnering opportunities - Platforms and AI") We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to: Chemistry - Artificial intelligence/Machine learning (AI/ML) approaches to accelerate discovery and synthesis of new molecular entities - Automated synthesis and profiling platforms - Novel cyclic peptide screening platforms ![Avi Spier](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/avi-spier.jpg.webp?itok=ILSvAUTj "Avi Spier") #### Avi Spier [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Biotherapeutics - Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery. - Targeted delivery and selective tropism to key tissues/cell types - Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates ![Gianfranco de Pascale](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/gianfranco-de-pascale.jpg.webp?itok=RG_Q7DsE "Gianfranco de Pascale") #### Gianfranco de Pascale [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Cell and gene therapy - Novel T-cell-based therapy approaches - Approaches to reduce AAV immunogenicity - NextGen gene editing (non-viral) - Novel approaches for selective gene expression in target cells for GTx ![Markus Werner](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/markus-werne.jpg.webp?itok=QFdRZ5O7 "Markus Werner") #### Markus Werner (Oncology) [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) ![Elizabeth Leshen](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/ellizabeth-leshen.JPG.webp?itok=1bFitdPb "Elizabeth Leshen") #### Elizabeth Leshen (Rare diseases and neuroscience) [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) xRNA - Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types - Innovative siRNA chemistry platforms - In vivo/In vitro platforms to identify and validate siRNA targets ![Gianfranco de Pascale](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/gianfranco-de-pascale.jpg.webp?itok=RG_Q7DsE "Gianfranco de Pascale") #### Gianfranco de Pascale [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Radioligand therapy - Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery - Explore various combination approaches which are synergistic with RLTs - Technologies to expand the therapeutic window of RLTs ![Shona Whyte portrait](/sites/novartis_com/files/styles/crop_freeform/public/2026-01/shona-whyte.jpg.webp?itok=1082kuf8 "shona-whyte") #### Shona Whyte [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Artificial intelligence | Machine learning | Digital We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to: - Enable deeper understanding of disease to identify novel therapeutic Targets - Power small and large molecule design and optimization - Increase predictive safety - Improve trial design and execution ![Cynthia Hong](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/cindy-hong.jpg.webp?itok=OI5r4slc "Cynthia Hong") #### Cynthia Hong [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) - [Print](/node/600101/printable/print) - [PDF](/node/600101/printable/pdf) ## [Partnering opportunities - Out licensing and divestments](/node/665681 "Partnering opportunities - Out licensing and divestments") Out licensing and divestments Novartis is open to discussing the divestment of certain commercial products in different regions, as well as granting licenses to development-stage compounds that have been de-prioritized due to strategic reasons. ![Sven Werner](/sites/novartis_com/files/styles/crop_freeform/public/2024-01/sven-werner.jpg.webp?itok=7LUift47 "Sven Werner") ### Out licensing #### Sven Werner [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) ![Person icon](/sites/novartis_com/files/styles/crop_freeform/public/2025-10/person-icon.png.webp?itok=jjbTirKt "Person icon") ### Divestments #### Jean Marc Séquier [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) - [Print](/node/665681/printable/print) - [PDF](/node/665681/printable/pdf) ## [Partnering opportunities - Other Areas](/node/600106 "Partnering opportunities - Other Areas") Precision medicine Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions. ![Guy Greiveldinger](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/guy-greiveldinger-portrait.jpg.webp?itok=selaGuxH "Guy Greiveldinger") #### Guy Greiveldinger [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) ![Frank Dieterle](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/frank-dieterle.jpg.webp?itok=S-ZCv1Jq "Frank Dieterle") #### Frank Dieterle [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) Global health Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases. ![Charles Bailey](/sites/novartis_com/files/styles/crop_freeform/public/2023-10/charlie-bailey.jpg.webp?itok=LwYzySTp "Charles Bailey") #### Charles Bailey [Contact](https://novartis.partneringplace.com/SubmissionUI/novartis/submission) - [Print](/node/600106/printable/print) - [PDF](/node/600106/printable/pdf) ## Discover more [ ![Novartis partnering present at a conference](/sites/novartis_com/files/styles/cards_1_3/public/2026-01/novartis-partnering-at-conference.jpg.webp?itok=coYQ9_LG "novartis-partnering-at-conference") ### Where to meet us See which events Novartis will be attending. ](/partnering/partnering-event-calendar) [ ![woman on stage talking and holding a microphone](/sites/novartis_com/files/styles/cards_1_3/public/2026-01/novartis-partnering-susanne-leadership-team.jpg.webp?itok=bYI_KXjr "novartis-partnering-susanne-leadership-team") ### Leadership team Get to know the Corporate & Business Development team (Photo: CEBD Group). ](/partnering/partnering-leadership-team) [ ![View from “Hohlweg” passing under the Novartis Pavillon](/sites/novartis_com/files/styles/cards_1_3/public/2023-03/view-from-hohlweg-passing-under-the-novartis-pavillon.jpg.webp?itok=OTN2OKef "View from “Hohlweg” passing under the Novartis Pavillon") ### Our approach Discover how we collaborate to address some of society's most challenging healthcare issues. ](/partnering/our-approach-partnering)